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Background: AMP activated protein kinase (AMPK) regulates key metabolic reactions and plays a major role in
glucose homeostasis. Activating the AMPK is considered as one of the potential therapeutic strategies in treating
type-2 diabetes. However, targeting AMPK by small molecule mediated approach can be challenging owing to
diverse isoforms of the enzyme and their varied combination in different tissues. In the current study we employ a
novel strategy of achieving AMPK activation through increasing the levels of cellular AMP (an allosteric activator of
AMPK) levels by activating the enzyme involved in AMP biosynthesis namely Adenylosuccinate lyase (ADSL).
Methods: Rat primary hepatocytes were cultured under metabolic overload conditions (500 μM palmitate) to
induce insulin resistance. ADSL was overexpressed in these hepatocytes and its effect on hepatic glucose output,
and triglyceride accumulation was checked. In addition to this, ADSL was overexpressed in high fat diet induced
obese mice by hydrodynamic tail vein injection and its effect on fasting glucose, glucose tolerance and pyruvate
tolerance were checked.
Results: Rat primary hepatocytes when cultured under metabolic overload conditions developed insulin resistance
as measured in terms of failure of insulin to suppress the glucose output. Overexpressing the ADSL in these
hepatocytes resulted in increased AMPK phosporylation and improved the insulin sensitivity and also resulted in
reduced triglyceride accumulation and inflammatory cytokine levels. In addition to this, when ADSL was
overexpressed in high fat diet induced obese mice, it resulted in reduced the fasting hyperglycemia (20% reduction),
and increased glucose and pyruvate tolerance.
Conclusions: This study indicates that activating ADSL can be a potential mechanism to achieve the activation of
AMPK in the cells. This leads to a novel idea of exploring the purine nucleotide metabolic pathway as a promising
therapeutic target for diabetes and metabolic syndrome.
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Metabolic disorders, more specifically Type 2 Diabetes,
obesity, cardiovascular diseases that result from both en-
vironmental and genetic factors are considered to be
some of the fastest growing public health problems glo-
bally. These conditions may be associated with reduced
insulin action and impaired glucose and lipid metabolism.* Correspondence: m.r.jagannath@connexios.com;
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unless otherwise stated.Several therapeutic options available today differ in their
mode of action, efficacy to lower blood glucose and associ-
ated complications and in their side effect profiles. Since
T2DM is a progressive disease worsening with time, the
available drugs need to be used in varied associations [1]
and there is a pressing need to develop new therapeutic
strategies to prevent and treat T2DM.
AMP-activated protein kinase (AMPK) is a phylogeneti-
cally conserved serine/threonine protein kinase, which acts
as an energy sensing enzyme in the cells and is activated in
response to cellular stresses that deplete the ATP levels inral Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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recent studies demonstrate AMPK as one of the probable
targets for antidiabetic action of leading drugs like met-
formin [4,5] and thiazolidinediones [4,6]. In addition,
chemical activation of AMPK with AICAR is shown to
improve blood glucose and lipid profile. Taken together
the above findings support the idea that AMPK can be
an attractive therapeutic target for T2DM and insulin
resistance [1,7]. However, developing a small molecule
which regulates AMPK activity can be quite challenging
considering the subtype complexity and tissue distribu-
tion of these isoforms [8].
The cellular energy status and AMPK activation are
coupled by AMP, an allosteric activator of AMPK. Hence
an indirect strategy to affect the AMPK activity would
be to target the pathways that generate AMP in the cell.
In the cell system, AMP is produced during purine nucleo-
tide cycling reaction and the enzyme that produces AMP
during biosynthesis is Adenylosuccinate lyase [(ADSL); EC
4.3.2.2.]. ADSL acts in two pathways of purine nucleotide
metabolism. It catalyses the conversion of succinylami-
noimidazole carboxamide ribotide (SAICAR) into aminoi-
midazole carboxamide ribotide (AICAR) in the purine de
novo synthesis pathway, and it also catalyses the formation
of adenosine monophosphate (AMP) from adenylosucci-
nate (S-AMP) in the purine nucleotide cycle [9,10]. We hy-
pothesized that increasing the levels of ADSL in the cell
would result in an increased AMP levels which in turn
should lead to activation of AMPK and a consequent bene-
fit on glycemic control. We evaluated this hypothesis using
rat primary hepatocytes and high fat diet induced obese
mouse model. Here we report that the ADSL overexpres-
sion in these two systems results in an increased insulin




An expression vector in which reading frame of ADSL is
placed under the control of CMV promoter was ob-
tained from Origene. In this expression vector ADSL is
presented as un-tagged protein in order to avoid arte-
facts arising due to N or C terminal tags. Restriction en-
zymes with respective buffers and T4DNA ligase were
from NEB. Trans-IT invivo gene delivery solution was
from mirus biosciences. C57B6J mice were from Jackson
laboratories USA.
Cell culture experiments
Routinely, the freshly isolated rat primary hepatocytes
were cultured in growth medium containing DMEM
supplemented with 10% fetal calf serum in a humidified
CO2 incubator at 37°C. For experiments involving ADSL
overeexpression, primary hepatocytes were transfectedwith the expression plasmid using Lipofectamine™ 2000
(Invitrogen). 24 hours following the transfection, the
cells were cultured in DMEM alone (referred to as nor-
mal culture condition) or in the DMEM medium con-
taining 500 μM palmitic acid (referred to as Metabolic
overload condition) for 24 hours. For experiments invol-
ving the measurement of glucose release, the adherent
hpeatocytes were washed with phosphate buffered saline
(PBS) and were incubated in the substrate medium (1%
fetal calf serum, 5 mM lactate, 5 mM pyruvate, 100 IU
penicillin, 100ug/ml streptomycin without glucose) with
or without 30nM insulin for 6 hours. The glucose released
into the media was estimated using glucose GOD - FS kit
(days) following manufacturer’s instructions. HepG2 cells
were cultured in DMEM supplemented with 10% fetal calf
serum and a similar procedure described for rat primary
hepatocytes was used for transfection. For estimation of the
total TAG (triacyl glycerol) in the cells, HepG2 cells were
cultured with or without palmiatate overlaod and after
48 hours cells were lysed in lysis buffer containing 50 mM
Tris HCl (pH-8), 150 mM NaCl and 0.5% Triton-X. The
clear lysaste was used for TAG estimation.
Preparation of palmitate
Sodium palmitate (Sigma Aldrich) was dissolved at
500 mM concentration in 50% ethanol solution. This
was further diluted to 5 mM using 10% FFA free BSA
solution. This solution was filter sterilized and was used
as stock solution.
Estimation of ATP and AMP
Cells were washed in ice-cold PBS and the entire contents
in the 24well plate were extracted into 95 μl of 0.3 M Per-
chloric acid and quickly transferred to centrifuge tube
(1.5 ml). Contents were neutralized by adding 95ul of 2 M
potassium hydroxide and the tube was vortexed and then
centrifuged at 10,0000 rpm for 10 minutes at 4°C to re-
move acid-insoluble fractions. Supernatant was used for
ATP and AMP estimations by LC-MS. RP-18 column was
used for ESI-MS and (90% Acetonitrile +10% Water +
0.1% Ammonium formate) and 0.1% aqueous ammonium
formate were used as mobile phase and gradient elution
method was used. The levels of AMP and ATP was calcu-
lated based on the AUC obtained for the standard concen-
trations of the respective species.
Western blot
Primary hepatocytes were lysed in lysis buffer (50 mM
Tris HCl pH-8, 150 mM NaCl and 0.5% Triton-X) and
the proteins in the lysate were separated by SDS-PAGE.
The bands were transferred to nitrocellulose membrane
and the blot was probed with phoshpo specific anti-AMPK
antibody (phsopho AMPK-α Thr-172 rabbit monoclonal
antibody reactive to rat isoform obtained from cell
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The bands were detected by chemiluminiscence.
Gene expression analysis
Trizol extraction was used for RNA isolation from cells
and tissues and the RNA was converted to cDNA. The ex-
pression levels of the gene were quantified by quantitative
real time PCR using MesaGreen (SYBR green master mix)
and gene specific primers. β-actin was used as endogenous
gene control. The sequence of the primers used in this
study is as follows:
MCP1 forward (rat) – 5′
ATGCAGTTAATGCCCCACTC 3′
MCP1 reverse (rat) –5′
TTCCTTATTGGGGTCAGCAC 3′
IL1- β forward (rat) – 5′
TGACCCATGTGAGCTGAAAG 3′
IL1- β reverse (rat) – 5′
GGGATTTTGTCGTTGCTTGT 3′
Animals and groups
C57B6/J male mice were housed in group of 3–4 ani-
mals in standard polypropylene cages with stainless steel
top grill having facilities for pelleted food and purified
drinking water in bottle. Animals had access to food and
water ad libitum. All animal experiments were approved
by the Connexios Institutional Animal Ethics Committee
(IAEC) which are in accordance with the ARRIVE guide-
lines and approved by the Committee for the Purpose of
Control and Supervision of Experiments on Animals.
Animals were housed at 22 ± 3°C, with a relative humid-
ity of 50-70% on a 12 hour light and 12 hour dark cycle
with artificial fluorescent tubes. 6 week old mice were
fed on high fat diet (D12492 60% Kcal, fat from lard
from Research Diets, US) for 13 weeks. After 13 weeks,
the mice on high fat diet were evaluated for development
of diabetic phenotype. Fasting glucose, body weight and
oral glucose tolerance were considered for randomization.
During randomization into groups, care was taken to
make sure that body weight, fasting glucose and oral
glucose tolerance values are not significantly different
across these groups. Based on these parameters these mice
were divided into 2 groups. One group of mice served as
control (HFD control) and the other group served as ‘test
group’ animals (designated as HFD +ADSL). Age and sex
matched mice, which were kept on a normal chow diet
(10% k.cal fat) were used as lean control in all the
experiments.
Gene delivery to mouse liver
The plasmid DAN used in these studies was endotoxin
free. Each mouse received 20 μg of the plasmid DNA de-
livered through hydrodynamic tail vein injection asexplained previously in literature [11,12]. Briefly, the
plasmid DNA was suspended in gene delivery solution,
the mouse was restrained and the solution was deliv-
ered through tail vein with a constant speed within
8 seconds. The volume of the gene delivery solution
was 1/10th of the body weight of the mice and did not
exceed 2.7 ml in any case. Mice in the control group
(HFD control) received empty vector in which the
ADSL sequences were absent. For the test group ani-
mals, the mice were injected with the plasmid expres-
sion vector. The mice received gene delivery once in
15 days. The lean control animals did not receive any
plasmid DNA injections.Measurement of blood glucose levels
Blood was withdrawn from the tail tip and blood glucose
was measured using Acuucheck instrument (Roche diag-
nostics). For the oral glucose tolerance test, animals were
fasted for 6 hours, and blood glucose levels were measured
at various time points following an oral glucose load of
2 g/kg (0, 15, 30, 60, 90, 120 minutes).Pyruvate tolerance test
Animals were fasted for 12 hours, and blood glucose levels
were measured (0 minute glucose). After recording the
0 minute levels, a pyruvate load of 2 g/kg bodyweight were
given to mice through oral gavage. Blood glucose levels
were measured at time intervals of 15 minutes, 30 minutes,
60 minutes, 90 minutes, 120 minutes.Results
ADSL expression is decreased in hepatocytes under
disease mimicking conditions
Earlier studies indicate that culturing hepatocytes with
saturated fatty acid and pro-inflammatory agents can re-
sult in ‘pathophysiological condition’ in vitro wherein
the hepatocytes show increased triglyceride accumula-
tion [13], gluconeogenesis [14,15]– the hall marks of
diabetic pathology. When rat primary hepatocytes were
cultured in presence of 500 μM palmitate, we observed
decreased insulin sensitivity, and increased inflammatory
cytokine expression and increased TAG accumulation in
HepG2 cells (discussed in subsequent sections) indicat-
ing that indeed palmitate overload in the culture media
induced disease mimicking conditions. We used this sys-
tem to represent ‘disease mimicking conditions’ in vitro
and tested if the ADSL expression was different when
cultured under palmitate overload conditions. As indi-
cated in Figure 1, the expression levels of ADSL were
significantly lower under metabolic overload conditions,























Figure 1 ADSL expression in the rat primary hepatocytes.
Rat primary hepatocytes were cultured under normal or
metabolic overload (MO) conditions and the level of expression
of ADSL was checked by real time quantitative PCR. Beta actin
was used as endogenous control and the level of expression of
ADSL under normal condition was normalized to the value of 1.
Unpaired students t-test was used to calculate the statistical
significance *** (p < 0.001).
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increase in AMP levels
We overexpressed ADSL in rat primary hepatocytes using
expression vector in which ADSL was cloned under the
control of a strong CMV promoter. In order to confirm
that the ADSL protein exhibits the expected activity in the
cells, we checked for the levels of AMP, which is a product
of enzymatic action of ADSL on its substrate IMP. As in-
dicated in the Figure-2A, cells overexpressing ADSL ex-
hibited increased AMP levels compared to respective
controls. As expected, ADSL overexpression resulted in





















Figure 2 AMP and ATP levels in the hepatocytes. Rat primary hepatocy
with or without ADSL overexpression. At the end of 24 hours, the AMP (
Unpaired students t-test was used to calculate the statistical significanceoverexpression there was about 12% increase in the
AMP levels in the hepatocytes cultured under normal
conditions. However, under disease mimicking condi-
tions ADSL overexpression resulted in about 25% in-
crease in the AMP levels. In our experiments we saw
that under metabolic overload conditions, the ATP
levels were slightly reduced (Figure 2B) and notably
the expression of ADSL did not alter the ATP levels
either under normal or metabolic overload conditions
(Figure 2B).
ADSL overexpression increases AMPK phosphorylation in
primary hepatocytes
AMPK is a major regulator of cellular energy homeo-
stasis and its enzymatic activity is stimulated through
phosphorylation of threonine-172 on the catalytic sub-
unit alpha, by an upstream AMPK kinase and through
allosteric activation by AMP through CBS (cystathionine
b-synthase) domains on the gamma subunits. AMPK is
typically susceptible to the AMP/ATP ratio, which in
turn is influenced by cellular and environmental stress,
such as heat shock, hypoxia, ischemia and metabolic
poisoning activates AMPK. In our study, we found that
subsequent to overexpression of ADSL, the AMP levels
were increased while the ATP levels remained unchanged
indicating an increase in AMP/ATP ratio (Figure-2A and
B) following ADSL expression. This increase indeed
reflected in an increase in the AMPK phosphoryl-
ation. AS shown in Figure 3, when ADSL was overex-
pressed under normal culture conditions, the increase
in the AMPK levels was very marginal (lane2). How-
ever the AMPK phosphorylation showed significant
increase with ADSL overexpression when the cells
were cultured under metabolic overload conditions
(Figure 3, lane4). This correlates well with the extent



















tes were cultured under normal or metabolic overload (MO) conditions
A) and ATP levels (B) were checked LC-MS based measurements.
* (p < 0.05) ** (p < 0.01).
pAMPK
ADSL - - ++
Normal MO
-Actin
Figure 3 Phospho-AMPK levels following ADSL overexpression.
Rat primary hepatocytes were cultured under normal or metabolic
overload (MO) conditions with or without ADSL overexpression.
At the end of 24 hours the cells were lysed and the pAMPK protein
levels (Thr-172 phosphorylated) were visualized by western blotting.
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of glucose release in primary hepatocytes
Elevated hepatic glucose production is a major contribu-
tor towards increased fasting glucose levels in diabetes
[1,17]. Insulin represses hepatic glucose output from the
liver and this is dysregulated in diabetic conditions leading
to elevated fasting glucose levels. As shown in Figure 4,
hepatocytes cultured under normal conditions respond to
insulin treatment and show about 43% decrease in the
glucose output. However, when cultured under disease
mimicking conditions (MO, 500 μM palmitate), the glu-
cose output from hepatocytes was about 2.5 fold higher
compared to normal and insulin treatment resulted only
in about 10% decrease in the glucose output indicating the


































Figure 4 Effect of ADSL overexpression on hepatic glucose output an
normal Normal or metabolic overload (MO) conditions. At the end of 24 ho
glucose released into the culture media either in the absence (control) or p
methods. Glucose released into the media was normalized to total cellular
significance ** (p < 0.01).background could restore the insulin sensitivity - as
shown in Figure 4, when ADSL was overexpressed in
the cells cultured under disease mimicking conditions,
they respond to insulin treatment and there was about
40% decrease in the glucose output in these cells.
ADSL overexpression decreases TG accumulation
in the liver
AMPK activation system is known to be a regulator of
ectopic lipids metabolism [1]. Activation of AMPK in
the liver is shown to decrease fatty acid biosynthesis and
increase mitochondrial fatty acid oxidation [1], owing to
this, AMPK activation is shown to significantly decrease
triglyceride storage in ectopic tissues like liver [18]. We
checked if ADSL overexpression and concomitant AMPK
activation can have any impact on liver triglyceride levels.
As shown in Figure 5 when hepatocytes were cultured
under metabolic overload conditions, there was about 2.8
fold increase in the triglyceride levels. When ADSL was
overexpressed in this background it resisted the increase
in TG indicating the beneficial effect of ADSL activation
under metabolic overload conditions.
ADSL overexpression decreases expression of acute
phase proteins in liver
Several prospective studies show that T2DM is a case of
chronic low grade inflammation and acute phase pro-
teins are shown to be elevated in diabetic conditions
[19] and they are even proposed as predictive markers




d insulin sensitivity. Rat primary hepatocytes were cultured under
urs the hepatic glucose output was estimated by measuring the
resence of 10nM of insulin (+insulin) as explained in materials and






























Figure 5 Effect of ADSL overexpression on hepatic triglyceride
content. HepG2 cells were cultured under Normal or metabolic
overload (MO) conditions. At the end of 48 hours, the cells were
lysed and triglyceride (TAG) levels were measured. The TAG levels
were normalized to total cellular protein. Unpaired students t-test
was used to calculate the statistical significance ** (p < 0.01).
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proteins were increased in hepatocytes (Figure 6).
Expression of ADSL in this background resulted in
significant reduction in the levels of acute phase
proteins.ADSL expression in the mouse liver
In order to further evaluate the effect of ADSL in vivo,
we overexpressed ADSL in the liver in DIO mice. Mice
which were kept on high fat diet for 13 weeks were de-
livered with ADSL expression vector through hydro-
dynamic gene delivery as explained in materials and
methods. Gene delivery was conducted intermittently
(every 15 days) in order to obtain a sustained overex-
pression. At the end of the study (4 weeks later), the
mice were sacrificed and the expression of the ADSL in
























Figure 6 Effect of ADSL overexpression on inflammatory cytokines. R
overload (MO) conditions for 24 hours. The m-RNA levels of MCP-1 (A) or I
used as endogenous control. Unpaired students t-test was used to calculatquantitative PCR and as shown in Figure 7, there was
about 3 fold increase in the ADSL levels in the test
group mice.
ADSL expression improves fasting glucose and pyruvate
tolerance
3 weeks following the gene delivery, the fasting glucose
levels were measured in the mice. As indicated in
Figure 8A mice expressing ADSL exhibited about a 20%
decrease in the fasting glucose levels. High fat diet in-
duced mice exhibit increased glucose output following
challenge with pyruvate a gluconeogenic substrate, and
this is due to uncontrolled gluconeogenesis. The pyru-
vate tolerance test is used routinely as a measure of
gluconeogenesis index invivo. When challenged with
pyruvate, the HFD control mice showed increased glu-
cose production and there was 56% increase in the
glucose-AUC when compared to mice fed on chow diet
(Figure 8B and 8C) indicating unregulated gluconeogen-
esis in these mice. When ADSL was overexpressed, the
glucose output in response to pyruvate challenge was
significantly low compared to HFD control mice - when
compared to untreated HFD mice, the ADSL expressing
mice exhibited 20% decrease in the glucose output as
measured by glucose – AUC (Figure 8C).
ADSL expression improves glucose tolerance
As indicated in Figure 9A, mice on HFD background
show increased glucose levels at all time points following
an oral glucose load. In terms of glucose AUC, the HFD
mice show about 60% increase in the glucose output
compared to lean mice on chow diet (Figure 9B). over-
expressing the ADSL in HFD mice resulted in marked
improvement in the glucose tolerance and in terms of
glucose AUC, the ADSL overexpressing mice showed
about 28% decrease in the glucose output indicating a



























at primary hepatocytes were cultured under Normal or metabolic
L-1b (B) were checked by real time quantitative PCR. Beta actin was






















Figure 7 ADSL overexpression in HFD mouse liver. Mice were
fed on high fat diet for 13 weeks and were divided into two groups
(n = 8 in each group). For one group, DNA construct expressing the
ADSL gene was injected through tail vein (HFD + ADSL), and control
group received plasmid that does not express ADSL (HFD control).
The gene delivery was conducted every. At the end of the study,
(4 weeks later) RNA was isolated from liver and ADSL gene
expression levels were quantified using Q-PCR. b-actin was used as
house keeping gene control. Unpaired students t-test was used to
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Figure 8 Effect of ADSL overexpression on fasting glucose and pyruv
divided into two groups (n = 8 in each group). For one group, DNA constru
control group received plasmid that does not express ADSL (HFD). 3 weeks
12 hours and fasting glucose levels were recorded (A) and pyruvate tole
the area under the curve during the pyruvate tolerance test was calcula
significance ** (p < 0.01), ***(p < 0.001).
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liver, but not in muscle and adipose indicating that im-
proved glucose uptake can be attributed to improved
insulin sensitivity of the liver. The relative import-
ance of liver as compared to other peripheral tissues
like muscle and adipose tissue in the uptake of an
oral glucose load has been estimated in earlier studies
and these studies have demonstrated that approxi-
mately 10% of the oral glucose load is trapped by the
liver on first passage through the portal system [21].
Also, the liver takes up approximately 50% of the
total amount of glucose escaping initial hepatic up-
take and thus is a major contributor of the glucose
uptake [22,23]. Insulin increases the levels of glucokinase
[24,25] and glycogen synthase activity in the liver [26]
which finally results in trapping the glucose inside the
liver as glycogen and this reaction in effect can facilitate
the glucose uptake by GLUT2 a glucose concentration
dependent glucose transporter present on the liver cells.
Hence insulin sensitivity acts as a positive influence on
hepatic glucose uptake, although GLUT2 is an insulin in-
dependent transporter. This is further evidenced by stud-
























ate tolerance. Mice were fed on high fat diet for 13 weeks and
ct expressing the ADSL gene was delivered to liver (HFD + ADSL), and
later (post gene delivery), both groups of mice were fasted for
rance was measured as indicated in materials and methods (B) and
ted (C). Unpaired students t-test was used to calculate the statistical
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Figure 9 Effect of ADSL overexpression on glucose tolerance. Mice were fed on high fat diet for 13 weeks and divided into two groups
(n = 8 in each group). For one group, DNA construct expressing the ADSL gene was delivered to liver (HFD + ADSL), and control group received
plasmid that does not express ADSL (HFD). 3 weeks later mice were fasted for 6 hours and glucose tolerance was measured as indicated in materials
and methods. (A) – Glucose levels at different time points after oral glucose load, (B) – Area under the curve between 0 min to 120 min.
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Purine nucleotides, apart from being a part of nucleic
acids, act as key regulators of vital functions of cell in-
cluding cell metabolism, cell proliferation and cell death.
They are the essential carriers of chemical energy such
as ATP. Purine metabolite state modulates the AMP/
ATP ratio and can impact mitochondrial function as well
as AMPK activity affecting key cellular functions such as
skeletal muscle oxidative capacity and glucose oxidation,
hepatic glucose output, glucose sensitivity and islet in-
sulin secretion – all of which can affect glucose homeo-
stasis. Under diabetic condition, metabolic stress can
lead to reduced mitochondrial function which can im-
pact the cellular ATP pools. This in conjunction with re-
duced glucose metabolism due to insulin resistance, can
result in reduced purine metabolites, making it rate limit-
ing for further cellular processes. Earlier studies indicate
that under insulin resistance and diabetic conditions, the
mitochondrial function is compromised leading to re-
duced ATP synthesis [28,29].
The importance of purine metabolism in metabolic
syndrome is supported further by literature evidences.
Adenosine A1 receptor signaling is shown to be impor-
tant for insulin controlled glucose homeostasis in mice
[30] and mice with adenosine receptor (A1AR) deletion
is shown to exhibit age dependent fat accumulation in
the body [31]. Adenosine, is a metabolic byproduct of
ATP utilization, is shown to have a positive effect on in-
sulin sensitivity and glucose handling [32,33]. Despite
several reports on the importance of the purinergic signa-
ling in glucose metabolism, the direct effect of manipula-
ting the purine metabolism on glucose homeostasis is
lacking in the literature.
ADSL is a homotetramer [34] involved in the purine
biosynthesis pathway. Several studies conducted in the
past focus on the significance of ADSL in neurophy-
siology – mutations leading to ADSL deficiency resultsin various neurological disorders ranging from mild
mental retardation in some cases to fatal neonatal en-
cephalopathy with hypokinesia [35-37]. However, eva-
luation of ADSL from metabolic syndrome perspective is
novel. Our present study demonstrates that by increa-
sing the AMP levels under disease conditions, one can
get the benefits on glycemic parameters possibly through
AMPK activation. Although in the present study we did
not extensively validate the small molecule targetability
and safety profile of ADSL with small molecule, it is in-
teresting to note that overexpression of ADSL in the
mouse model did not have any detectable pathology, and
did not show any noticeable change in the behavior/
health during the course of our study. The overexpres-
sion strategy used in this study has limitations and one
cannot control the extent of activation. Using a small
molecule based approach can provide a lot more flexibi-
lity in terms of extent of activation. Hence, with a small
molecule based approach one can have control over the
extent of physiological effect. Our study provides preli-
minary data supporting the possibility of exploring ADSL
as a target for metabolic syndrome.
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